ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 567 • 2014 ACR/ARHP Annual Meeting

    Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata® Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab

    Denis Choquette1, Louis Bessette2, Isabelle Fortin3, Boulos Haraoui1, Jean Pierre Pelletier1, Jean-Pierre Raynauld1, Diane Sauvageau1, Edith Villeneuve1 and Louis Coupal1, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, 3Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada

    Background/Purpose: Anti-TNF agents namely adalimumab (ADA), etanercept (ETA) and infliximab (INF) are approved for the treatment of signs and symptoms of ankylosing spondylitis. Their efficacy…
  • Abstract Number: 102 • 2014 ACR/ARHP Annual Meeting

    Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom

    Frances Humby1, Stephen Kelly1, Angela V. Bedenbaugh2, Nawab Qizilbash3,4, Jochen Dunkel5, Belén SanJose3, Ignacio Mendez3, Jennifer Timoshanko6 and Jeyanesh Tambiah2, 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 2UCB Pharma, Smyrna, GA, 3OXON Epidemiology, London, United Kingdom, 4Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom, 5UCB Pharma, Monheim, Germany, 6UCB Pharma, Slough, United Kingdom

    Background/Purpose Several anti-TNFs are currently approved in Europe for RA treatment including certolizumab pegol (CZP), adalimumab (ADA), etanercept (ETN), golimumab and infliximab. UK NICE guidance…
  • Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting

    Serum Survivin in Early Rheumatoid Arthritis

    Adrian Levitsky1, Malin Erlandsson2, Maria Bokarewa2 and Ronald F. van Vollenhoven3, 1The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, 2Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 3Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden

    Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
  • Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting

    Proton Rahman1, Denis Choquette2, William Bensen3, Majed Khraishi4, Saeed Shaikh5, Regan Arendse6, Isabelle Fortin7, Andrew Chow8, Maqbool Sheriff9, Eliofotisti Psaradellis10, John S. Sampalis10, Susan Otawa11, Francois Nantel12, Allen J Lehman11 and May Shawi12, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, 3Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, 4Nexus Clinical Research, St John's, NF, Canada, 5McMaster University, Hamilton, ON, Canada, 6University of Saskatchewan, Saskatoon, SK, Canada, 7Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, 8University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, 9Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada

    Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
  • Abstract Number: 566 • 2014 ACR/ARHP Annual Meeting

    Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis

    Désirée M. van der Heijde1, Walter P. Maksymowych2, Robert B. M. Landewé3, Christian Stach4, Owen Davies5, Tommi Nurminen4 and Jürgen Braun6, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4UCB Pharma, Monheim, Germany, 5UCB Pharma, Slough, United Kingdom, 6Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

    Background/Purpose The impact of certolizumab pegol (CZP) on clinical and Magnetic Resonance Imaging outcomes in patients (pts) with axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS)…
  • Abstract Number: 75 • 2014 ACR/ARHP Annual Meeting

    Robust Identification of Anti-TNF Non-Responders in RA from Blood

    Ty Thomson, Reynald Lescarbeau, David Drubin, David Fryburg, David de Graaf, Renée Deehan, Daphna Laifenfeld and Aaron Van Hooser, Selventa, Cambridge, MA

    Background/Purpose: The number of biologic therapies approved for use in treating rheumatoid arthritis (RA) has grown steadily over the past 15 years.  While many patients…
  • Abstract Number: 2500 • 2014 ACR/ARHP Annual Meeting

    Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients

    Jacob Sode1,2,3, Ulla Vogel4, Steffen Bank5,6, Paal Skytt Andersen7, Merete Lund Hetland8,9, Henning Locht3, Niels H. H. Heegaard10,11 and Vibeke Andersen1,5,12,13, 1Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark, 2Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Copenhagen S, Denmark, 3Department of Rheumatology, Frederiksberg Hospital, Frederiksberg, Denmark, 4National Research Centre for the Working Environment, Copenhagen, Denmark, 5Medical Department, Viborg Regional Hospital, Viborg, Denmark, 6Institute of Human Genetics, University of Aarhus, Aarhus, Denmark, 7Microbiology & Infection Control, Statens Serum Institut, Copenhagen S, Denmark, 8Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, 9Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark, 10Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark, 11Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, Odense C, Denmark, 12Medical Department, Hospital of Southern Jutland Aabenraa, Aabenraa, Denmark, 13Odense University Hospital, OPEN (Odense Patient data Explorative Network), Odense, Denmark

    Genetic Variation in the TLR5 Locus is Associated with Anti-TNF Response among Rheumatoid Arthritis PatientsBackground/Purpose: In a recent study (paper in press) of Danish rheumatoid…
  • Abstract Number: 1528 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies

    Ronald van Vollenhoven1, S. B. Cohen2, Philip J. Mease3, Charles G. Peterfy4, Wolfgang Spieler5, Judith Boice6, Sean Curtis7, Qing Li7, Ruji Yao8, Richard Baumgartner7 and Holly Weng8, 1Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, 2Metroplex Clinical Research Center, Dallas, TX, 3University of Washington, Seattle, WA, 4Spire Sciences LLC, Boca Raton, FL, 5Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, 6Merck Research Laboratories, Whitehouse Station, NJ, 7Merck & Co., Inc, Whitehouse Station, NJ, 8Merck & Co., Inc., Whitehouse Station, NJ

    Background/Purpose:   Novel, targeted small-molecular medications are needed in the treatment of rheumatoid arthritis (RA).  MK-8457 is a novel inhibitor of spleen tyrosine kinase (SYK)…
  • Abstract Number: 565 • 2014 ACR/ARHP Annual Meeting

    Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis

    Jürgen Braun1, Walter P. Maksymowych2, Robert B. M. Landewé3, Christian Stach4, Owen Davies5, Tommi Nurminen4 and Desiree van der Heijde6, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 4UCB Pharma, Monheim, Germany, 5UCB Pharma, Slough, United Kingdom, 6Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose Previous results from RAPID-axSpA (NCT01087762) demonstrated that certolizumab pegol (CZP) reduced inflammation in the sacroiliac joints (SIJ) and spine, as assessed by Magnetic Resonance…
  • Abstract Number: 2495 • 2014 ACR/ARHP Annual Meeting

    Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis:   5-Year Data from 3 Phase III Clinical Trials

    Chenglong Han1, Edward C. Keystone2, Roy Fleischmann3, Josef Smolen4, Eric L. Matteson5, Paul Emery6, Mark C Genovese7, Timothy A. Gathany1 and Elizabeth C. Hsia8,9, 1Janssen Global Services, LLC., Malvern, PA, 2University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, 3Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, 4Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 5Rheumatology, Mayo Clinic, Rochester, MN, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Stanford University Medical Center, Palo Alto, CA, 8Janssen Research & Development, LLC., Spring House, PA, 9University of Pennsylvania, Philadelphia, PA

    Background/Purpose: To assess the impact of golimumab (GLM) on physical function and employability in patients with rheumatoid arthritis (RA) with various prior treatment histories, after…
  • Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting

    Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers

    Anaïz Nutz1, Yohan Duny2, Thomas Barnetche3, Jacques Morel4, Bernard Combe5 and Claire Daien6, 1Rheumatology, Hopital Lapeyronie, Montpellier, France, 2INSERM, Montpellier, France, 3Department of rheumatology, Bordeau, France, 4Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France, 5Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 6Hopital Lapeyronie, Montpellier, France

    Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…
  • Abstract Number: 545 • 2014 ACR/ARHP Annual Meeting

    Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure

    Philip J. Mease1, Roy Fleischmann2, Jurgen Wollenhaupt3, Atul A. Deodhar4, Dafna D. Gladman5, Bengt Hoepken6, Luke Peterson7 and Désirée M. van der Heijde8, 1Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, 2Rheumatology, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 3Division of Reheumatology, Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 4Oregon Health and Sciences University, Portland, OR, 5University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6UCB Pharma, Monheim, Germany, 7Biostatistics US Group, UCB Pharma, Raleigh-Durham, NC, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose Previous reports of RAPID-PsA (NCT01087788) demonstrated efficacy and safety of certolizumab pegol (CZP) over 48 weeks (wks) in psoriatic arthritis (PsA) patients (pts), including…
  • Abstract Number: 2475 • 2014 ACR/ARHP Annual Meeting

    Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study

    Edward C. Keystone1, Josef Smolen2, Vibeke Strand3, Thomas Kumke4, Irina Mountian5, Susan Walker6 and Robert B. M. Landewé7,8, 1University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, 2Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 3Biopharmaceutical Consultant, Portola Valley, CA, 4UCB Pharma, Monheim, Germany, 5UCB Pharma, Brussels, Belgium, 6UCB Pharma, Raleigh, NC, 7Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 8Atrium Medical Center, Heerlen, Netherlands

    Background/Purpose Use of imputed or observed data, as well as the patient (pt) population evaluated (eg. intention-to-treat [ITT], completer), affects the interpretation of long-term efficacy…
  • Abstract Number: 1472 • 2014 ACR/ARHP Annual Meeting

    Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes

    Maria Sole Chimenti, Alberto Bergamini, Eleonora Baffari, Eleonora Ballanti, Alessia Musto, Paola Conigliaro and Roberto Perricone, Rheumatology, allergology and clinical immunology, Department of "Medicina dei Sistemi", University of Rome "Tor Vergata", Rome, Italy

    Background/Purpose Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by infiltration of the synovium by inflammatory cells that destroys the cartilage and the…
  • Abstract Number: 544 • 2014 ACR/ARHP Annual Meeting

    Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis

    James T. Rosenbaum1,2, Martin Rudwaleit3, Robert B. M. Landewé4, Helena Marzo-Ortega5,6, Joachim Sieper7, Désirée M. van der Heijde8, Owen Davies9, Christian Stach10, Tommi Nurminen10 and Atul A. Deodhar11, 1OHSU, Portland, OR, 2Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, 3Endokrinologikum, Berlin, Germany, 4Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, 5Leeds Teaching Hospitals NHS Trust and NIHR Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 6University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 7Rheumatology Department,, University Hospital Charité, Berlin, Germany, 8Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Monheim, Germany, 11Oregon Health and Sciences University, Portland, OR

    Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation in the spine and sacroiliac joints, but can also manifest as inflammation at extra-spinal sites, most commonly…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology